Drugmakers skeptical of introduction of PSUR system

Published: 2010-08-31 06:58:00

Updated: 2010-08-31 06:58:00

Contrary to government intention, pharmaceutical firms here believe Korea's ambitious goal to effective ex post facto drug management through introduction of Periodic Safety Update Report (PSUR) in the proposed drug renewal system will not be progressing as well as initially hoped.

PSUR tracks...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK